Teneligliptin
As of the edition of 20 October 2026, Teneligliptin is a small molecule: marketed, first approved in 2012 (JP); acts on DPP4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- Brand name
- Tenelia
- First approved
- 29 June 2012 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Mitsubishi Tanabe Pharma
- Registered trials
- 28, 0 stopped early
- Disease areas
- Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DPP4 | Dipeptidyl peptidase 4 | P27487 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 14 | 14 | 0 | 0 |
| Phase 4 | 6 | 5 | 0 | 0 |
| All trials | 28 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Mitsubishi Tanabe Pharma | Applicant | 2012 to now |